Clinical trials: Dissection of Aorta, Thoracic
Non-small Cell Lung Cancer (NSCLC)
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC
- Trial name
- NCT00850577
- Testing
- Paclitaxel, Carboplatin, CT-322
- Where
- 55 sites in United States, Brazil and 6 more
- Volunteers
- 255 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Non-small-cell Lung
Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)
The purpose of this trial is to study how long patients can remain progression free when they receive CP-675,206, compared to how long patients can remain progression free when they receive best supportive care.
- Trial name
- NCT00312975
- Testing
- CP-675,206, best supportive care
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 90 people
- Sponsor
- AstraZeneca
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
The purpose of this study is to determine the maximum dose that is safely tolerated of the experimental drug Rhenium Re 188 P2045.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Neoplasm Recurrence, Local
- Trial name
- NCT00100256
- Testing
- Rhenium (Re 188 P2045, BAY86-5284)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Andarix Pharmaceuticals
Non Small Cell Lung Cancer
A Study in Non Small Cell Lung Cancer
LY2603618 is a selective inhibitor of the deoxyribonucleic acid (DNA) damage checkpoint kinase 1 (CHK1). It was being developed as a chemotherapeutic-enhancing agent in the treatment of cancer.
- Trial name
- NCT01139775
- Testing
- Pemetrexed, Cisplatin, LY2603618
- Where
- 24 sites in Germany, Spain
- Volunteers
- 76 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Carcinoma
RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer
This is a study to investigate the potential clinical benefit of roniciclib when given in combination with chemotherapy Carboplatin / Etoposide or Cisplatin / Etoposide as first line treatment in patients with extensive disease…
- Trial name
- CONCEPT-SCLC (NCT02161419)
- Testing
- Roniciclib (BAY1000394)
- Where
- 32 sites in United States, Belgium and 7 more
- Volunteers
- 142 people
- Sponsor
- Bayer
Lung Cancer
To Establish a Molecular Typing System for Early Diagnosis of Lung Cancer
This topic to take large multicenter study real world, the advanced liquid biopsy will ctDNA methylation detection technique is applied to pulmonary nodules differential diagnosis and early lung cancer screening, validation of…
- Trial name
- NCT05432128
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Singlera Genomics Inc.
Solid Tumors Harboring NTRK Fusion
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3).
- Trial name
- NAVIGATE (NCT02576431)
- Testing
- BAY2757556 (Larotrectinib, Vitrakvi)
- Where
- 98 sites in United States, Argentina and 23 more
- Volunteers
- 215 people
- Sponsor
- Bayer
NSCLC
LUMINIST: LUng Cancer Molecular Insights Non Interventional Study
The recent development of therapies targeting specific biomarkers mutations is changing the standards of care and prognosis of patients with advanced NSCLC, but very few data are currently available on those emerging biomarkers.
- Trial name
- LUMINIST (NCT02300831)
- Testing
- Data Collection
- Where
- 85 sites in Australia, Austria and 21 more
- Volunteers
- 770 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer, Neuroendocrine Cancer
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
This is a multicenter, open-label Phase I/II study consisting of two parts: Part 1 is a Phase I dose-escalation study of ZG006, aimed at evaluating the safety and tolerability of ZG006 in Participants with advanced small-cell…
- Trial name
- NCT06283719
- Testing
- ZG006
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Pulmonary Nodule, Solitary, Lung Cancer
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule.
- Trial name
- NIGHTINGALE (NCT06426628)
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 2,400 people
- Sponsor
- Veracyte, Inc.
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer
Study of XB010 in Subjects With Solid Tumors
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT06545331
- Testing
- XB010, Pembrolizumab
- Where
- 20 sites in United States, United Kingdom
- Volunteers
- 396 people
- Sponsor
- Exelixis
Carcinoma, Non-Small-Cell Lung
Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients
The National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) has informed AstraZeneca that the BR24 Phase II/III study of cediranib at 30mg in first line non-small cell lung cancer (NSCLC) will not continue into Phase…
- Trial name
- NCT00539331
- Testing
- AZD2171, Paclitaxel, Carboplatin
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Other Specified Injury of Thoracic Aorta
Study of the Relay Pro® Thoracic Stent-Graft in Subjects With Traumatic Injury of the Descending Thoracic Aorta
The purpose of this study is to investigate the safety and effectiveness of the RelayPro Thoracic Stent-Grafts in subjects with traumatic injury of the descending thoracic aorta (DTA)
- Trial name
- NCT03090230
- Testing
- Relay Pro Thoracic Stent-Graft System
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- Bolton Medical
Carcinoma, Non-Small-Cell Lung
Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer
The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.
- Trial name
- NCT00622193
- Testing
- anamorelin HCl
- Where
- 33 sites in United States, India
- Volunteers
- 228 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Lung Neoplasms
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the treatment of advanced stage…
- Trial name
- NCT00074854
- Testing
- CP-547,632
- Where
- 20 sites in United States
- Volunteers
- 87 people
- Sponsor
- Pfizer
Penetrating Ulcer of Aorta, Aneurysm Aortic
Evaluation of the Valiant Captivia Physician Fenestrated Stent Graft System in Aortic Arch and Descending Thoracic Aorta Pathologies
The study objectives are to assess safety and effectiveness, measured acutely and at the 30-day visit after implantation of the Valiant Captivia physician fenestrated Stent Graft.
- Conditions
- Penetrating Ulcer of Aorta, Aneurysm Aortic, Type B Aortic Dissection, Residual Dissection After Type A Repair
- Trial name
- EVERGREEN (NCT05479305)
- Testing
- The Valiant Captivia Stent Graft
- Where
- 4 sites in France
- Volunteers
- 30 people
- Sponsor
- Ceric Sàrl
Pleural Effusion, Pleural Effusion, Malignant
Use of Guidance Videos to Increase Engagement and Decrease Anxiety in Patients Undergoing Pleural Tap
Patients planned to undergo a pleural tap will get verbal explanation or watch a personalized guidance video in addition to verbal explanation.
- Conditions
- Pleural Effusion, Pleural Effusion, Malignant, Pleural Pleurisy Effusion
- Trial name
- NCT04254445
- Testing
- Personalized training video
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- GistMed Ltd.
Abdominal Injury, Thoracic Diseases
A Post Market Study to Confirm the Safety and Performance of the Signia™ Stapling System.
The objectives of this prospective, two-arm, multicenter post-market study is to confirm safety and performance through the incidence of subjects reporting serious adverse device effects (ADEs) up to and including 30 days…
- Trial name
- NCT03515811
- Testing
- Signia™ Stapling System
- Where
- 11 sites in United States, Canada and 3 more
- Volunteers
- 136 people
- Sponsor
- Medtronic - MITG
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Small Cell Lung Cancer
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and…
- Trial name
- ALISCA-Lung1 (NCT06095505)
- Testing
- Alisertib
- Where
- 30 sites in United States
- Volunteers
- 120 people
- Sponsor
- Puma Biotechnology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.